Loading
Rezatapopt is an experimental pill from PMV Pharma, in phase 2 trials for solid tumours with the TP53 Y220C mutation.
Rezatapopt (PC14586) is a small molecule, oral from PMV Pharma. Binds the p53 protein made from the TP53 Y220C mutation, stabilising it so that it can work again as a tumour suppressor. It is being developed for any tumour type with the TP53 Y220C mutation, in the phase 2 part of the PYNNACLE study (NCT04585750); a study in myelodysplastic syndrome and acute myeloid leukaemia (NCT06616636) and a drug-interaction study (NCT07372625) are also recruiting. The company reports an FDA Fast Track designation.
Binds the p53 protein made from the TP53 Y220C mutation, stabilising it so that it can work again as a tumour suppressor. Connects to TP53.
1.Rezatapopt slips into a pocket on TP53.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Rezatapopt" OR ABSTRACT:"Rezatapopt" OR TITLE:"PC14586" OR ABSTRACT:"PC14586") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Rezatapopt, not a curated reading list.
Shares TP53 and the tag pipeline.
Shares TP53 and the tag pipeline.
Shares TP53 and the tag pipeline.
Shares TP53 and the tag pipeline.
Shares TP53 and the tag pipeline.
Shares The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE), TP53.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/